Leukemia, Myeloid: all 2,432 studies

Page 20 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01034410Phase 2
• Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 1
• IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)TerminatedNCT01027923Phase 1
• Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01024127
• Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
• Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell TransplantationCompletedNCT01020175Phase 3
• An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT01019161Phase 1
• Unrelated Double Umbilical Cord Blood Units TransplantationStatus unknownNCT01015742Phase 2/3
• Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell TransplantationCompletedNCT01015196Phase 2/3
• A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)WithdrawnNCT01011998Phase 2
• Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) PatientsSuspendedNCT01010373Phase 2
• Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaCompletedNCT01005277
• Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720CompletedNCT01004965
• Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
• Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)CompletedNCT01001143Phase 1
• Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose CytarabineCompletedNCT00995332Phase 1/2
• Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
• Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00990054Phase 1
• Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesCompletedNCT00981240Phase 1
• Study of Dosage Individualisation for the Treatment of Acute Myeloid LeukemiaCompletedNCT00969891
• Intraosseous Infusion of Unrelated Cord Blood GraftsTerminatedNCT00967525Not applicable
• Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction CourseWithdrawnNCT00967512Phase 2
• Allogeneic Stem Cell Transplantation in CML With Partial T Cell DepletionStatus unknownNCT00966810Phase 2/3
• Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1
• Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
• Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
• Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
• Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid LeukemiaCompletedNCT00947830
• Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 MutationsCompletedNCT00943943Phase 1
• A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsWithdrawnNCT00943553Phase 2
• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
• Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2CompletedNCT00931138Phase 3
• A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years OldCompletedNCT00927498Phase 3
• Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)CompletedNCT00926731Phase 1
• GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyCompletedNCT00925873Phase 3
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
• Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
• Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesCompletedNCT00915785Phase 2
• Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00915252Phase 2
• MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
• Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)CompletedNCT00909168Phase 2/3
• Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT00908167Phase 1
• Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseApproved for marketingNCT00905593
• Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 1
• QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00900809Phase 1
• Studying Tissue and Blood Samples From Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00900224
• Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00898456
• Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaStatus unknownNCT00898092
• Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2CompletedNCT00896701
• Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line TherapyCompletedNCT00896129
• Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid LeukemiaTerminatedNCT00895297Phase 2
• Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
• Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeCompletedNCT00893373Phase 2
• Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeCompletedNCT00892190Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
• A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
• Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)CompletedNCT00880243Phase 3
• A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
• Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid LeukemiaCompletedNCT00867672Phase 2
• A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid LeukemiaCompletedNCT00866736Phase 2
• PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic TransplantationWithdrawnNCT00866346Phase 1
• Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid LeukemiaCompletedNCT00866073Phase 2
• A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00861874Phase 1
• Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskCompletedNCT00860639Phase 3
• Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyCompletedNCT00858806Phase 2
• Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
• Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasTerminatedNCT00852709Phase 1
• Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedNCT00852566Phase 2
• Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1/2
• Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic TrioxideCompletedNCT00850304Phase 2
• Glivec in Pediatric Chronic Myeloid Leukemia (CML)CompletedNCT00845221Phase 4
• Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00844441Not applicable
• Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00840684Phase 1/2
• Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
• Lenalidomide In Patients With Acute Myeloid LeukemiaTerminatedNCT00839059Phase 1
• Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00834002Phase 1
• Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00816283Phase 1
• Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug TherapyCompletedNCT00815321Phase 2
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
• Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00809211Phase 2
• A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesCompletedNCT00807677Phase 1
• Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid LeukemiaCompletedNCT00806325
• Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer CellsStatus unknownNCT00799799Phase 1
• Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
• SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)TerminatedNCT00798213Phase 2
• Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid LeukemiaCompletedNCT00797758Phase 2
• Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell TransplantationCompletedNCT00795548Phase 2
• Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
• Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 YearsCompletedNCT00783653Phase 1/2
• Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AMLCompletedNCT00780598Phase 2
• Sirolimus in Combination With MEC in High Risk Myeloid LeukemiasCompletedNCT00780104Phase 1
• Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)TerminatedNCT00779480Phase 1
• Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
• HCT Versus CT in Elderly AMLTerminatedNCT00766779Phase 3
• A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML)CompletedNCT00764231Phase 2

← Leukemia, Myeloid overview